Figure 3.

Recombinant pGP3 alleviated psoriasis-like signs in imiquimod (IMQ)-treated mice. (A) Imiquimod induced psoriasis-like lesions on mouse skin. (B) Topical application of pGP3 alleviated the psoriasis-like lesions in a dose-dependent manner. In contrast, no effects were observed when the chlamydial protein CT795C instead of pGP3 was topically applied. (C) Similar results as in panel (B) were observed when pGP3 or CT795 was injected subcutaneously into the skin area treated with imiquimod.